Our Mission

Our mission is to create health, not just fight disease. We leverage computational systems to create new bio technologies designed to optimize systemic performance and health span, to reverse degenerative conditions like Alzheimer’s, Parkinson’s, and other age-related disorders.

Current Research

MaxWell's hypothesis is that the aging human immune system makes the brain vulnerable to microbial infection, especially spirochete bacteria, leading to Age Related Immuno-Dementia (ARID). MaxWell researches the most important molecules found in the human immune system to develop novel therapeutics for Alzheimer's Disease and other related forms of ARID. MaxWell's strategy is to develop synthetic peptoid structures with uniquely powerful properties that engage the bodies’ own healing function. MaxWell is currently developing "Peptoid 1" which is a biomimic of human cathelicidin antimicrobial peptide LL-37 as a broad spectrum antimicrobial drug. This is our lead candidate for study in age related immune-dementia.

Age-Related Dementias

To date, there’s been no known cure for Alzheimer’s disease or age-related dementias. There is a great need for quicker, more accurate diagnosis of Alzheimer’s, in addition to a therapy for slowing and reversing effects. There are 5 therapies recommended by the Alzheimer’s Association and all of them only either alleviate symptoms or delay the disease.

The numbers:

Alzheimer’s disease, the most common form of dementia, is the 6th leading cause of death in the United States and 1st in the UK¹.
Today, there are 5.7 million people diagnosed with Alzheimer’s disease in the United States and this number is projected to nearly triple to 14 million people by 2060².
On average, victims suffer for 8-10 years [R] with 1-4 family members providing care.
Caring for victims of Alzheimer's costs as estimated $100 billion annually³, just in the United states.